1-3 of 3
Thomas Lund, MD
Close
Save search
Sort by
Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Free
Niels W. C. J. Van De Donk, MD PhD, Bronno van der Holt, PhD, Fredrik H. Schjesvold, MD PhD, Ka Lung Wu, MD, Stefano Spada, Annemiek Broyl, MD PhD, Wilfried Roeloffzen, Alain Gaddiseur, Thomas Lund, MD, Monique C. Minnema, Massimo Offidani, Mariella Grasso, Niels Frost Andersen, Jo Caers, MD PhD, Benedetto Bruno, MD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Roman Hajek, Prof, MD PhD, Reuben Benjamin, MD, Francesca Gay, MD, Annette Juul Vangsted, MD PhD, Pellegrino Musto
Journal: Blood
Blood (2019) 134 (Supplement_1): 693.
https://doi.org/10.1182/blood-2019-125120
Published: 2019
Journal Articles

High Dose Simvastatin Has No Beneficial Effect on Markers of Bone Turn-Over in Multiple Myeloma.

Free
Teis E. Sondergaard, MSc, Per T. Pedersen, MD, Thomas L. Andersen, MSc, Thomas Lund, MD, Patrick Garnero, PhD, Jean-Marie Delaisse, PhD, Torben Plesner, MD
Journal: Blood
Blood (2007) 110 (11): 4824.
https://doi.org/10.1182/blood.V110.11.4824.4824
Published: 2007
Journal Articles

Bortezomib Transiently Inhibits Osteoclast Resorptive Activity in Cell Culture Conditions Mimicking In Vivo Intermittent Treatment.

Free
Patrice Boissy, PhD, Thomas Lund, MD, Thomas L. Andersen, MSc, Torben Plesner, MD, Jean-Marie Delaisse, PhD
Journal: Blood
Blood (2006) 108 (11): 3508.
https://doi.org/10.1182/blood.V108.11.3508.3508
Published: 2006